ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9707
-0.08%
Brent Oil
83.195
0.08%
Bitcoin
64,319.42
0.50%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. vTv Therapeutics Inc (VTVT)

  7. vTv Therapeutics Inc (VTVT) Noticias

VTVT

vTv Therapeutics (VTVT)

vTv Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:VTVT
FechaHoraFuenteTítuloSímboloCompañía
19/03/202407:30PR Newswire (US)CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMITNASDAQ:VTVTvTv Therapeutics Inc
13/03/202407:00GlobeNewswire Inc.vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdateNASDAQ:VTVTvTv Therapeutics Inc
07/03/202415:47Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VTVTvTv Therapeutics Inc
07/03/202413:34Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:VTVTvTv Therapeutics Inc
05/03/202418:52Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:VTVTvTv Therapeutics Inc
05/03/202407:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
04/03/202407:00GlobeNewswire Inc.vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 DiabetesNASDAQ:VTVTvTv Therapeutics Inc
01/03/202407:00GlobeNewswire Inc.vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:VTVTvTv Therapeutics Inc
28/02/202408:14Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VTVTvTv Therapeutics Inc
28/02/202407:00GlobeNewswire Inc.vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D FundNASDAQ:VTVTvTv Therapeutics Inc
22/02/202415:00PR Newswire (US)CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCENASDAQ:VTVTvTv Therapeutics Inc
09/11/202315:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VTVTvTv Therapeutics Inc
09/11/202315:30GlobeNewswire Inc.vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate UpdateNASDAQ:VTVTvTv Therapeutics Inc
08/11/202307:00GlobeNewswire Inc.vTv Therapeutics to Participate at the Stifel 2023 Healthcare ConferenceNASDAQ:VTVTvTv Therapeutics Inc
02/11/202307:00GlobeNewswire Inc.vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical OfficerNASDAQ:VTVTvTv Therapeutics Inc
01/11/202307:00GlobeNewswire Inc.vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 MillionNASDAQ:VTVTvTv Therapeutics Inc
27/09/202307:30PR Newswire (US)CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19NASDAQ:VTVTvTv Therapeutics Inc
26/09/202307:30PR Newswire (US)Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic CancerNASDAQ:VTVTvTv Therapeutics Inc
25/09/202315:20Edgar (US Regulatory)Form DEF 14C - Other definitive information statementsNASDAQ:VTVTvTv Therapeutics Inc
18/09/202307:30PR Newswire (US)CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMANASDAQ:VTVTvTv Therapeutics Inc
15/09/202315:17Edgar (US Regulatory)Form PRE 14C - Other preliminary information statementsNASDAQ:VTVTvTv Therapeutics Inc
11/08/202315:30GlobeNewswire Inc.vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate UpdateNASDAQ:VTVTvTv Therapeutics Inc
10/08/202307:33PR Newswire (US)Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast CancerNASDAQ:VTVTvTv Therapeutics Inc
26/06/202315:25Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VTVTvTv Therapeutics Inc
21/06/202315:20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VTVTvTv Therapeutics Inc
16/06/202307:00GlobeNewswire Inc.vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive DeclineNASDAQ:VTVTvTv Therapeutics Inc
15/06/202306:33PR Newswire (US)CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTONNASDAQ:VTVTvTv Therapeutics Inc
24/05/202308:00GlobeNewswire Inc.vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex PharmaceuticalsNASDAQ:VTVTvTv Therapeutics Inc
11/05/202315:15GlobeNewswire Inc.vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate UpdateNASDAQ:VTVTvTv Therapeutics Inc
11/05/202315:10Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:VTVTvTv Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VTVT

Su Consulta Reciente

NASDAQ
AAPL
Apple
NASDAQ
QQQ
Invesco QQQ Trust Series 1
SPI
SP500
S&P 500
NYSE
CVX
Chevron
NYSE
MCD
McDonalds
NASDAQ
AMZN
Amazon.com
NYSE
AXP
American Express
AMEX
XLV
Health Care Select Sector
NASDAQ
NVDA
NVIDIA
NYSE
MRK
Merck
COIN
SOLUSD
Solana
NYSE
DIS
Walt Disney
PM
XAUUSD
Gold vs US Dollar
COIN
BTCUSD
Bitcoin
USOTC
ADDYY
Adidas (QX)
CCOM
SILVER
SILVER
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados